Business Context and Reporting Period
Company: Cartesian Therapeutics, Inc. (RNAC)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: A late clinical-stage biotechnology company developing mRNA-based cell therapies for autoimmune diseases. The lead candidate, Descartes-08, is in Phase 3 for myasthenia gravis (MG) and Phase 2 for dermatomyositis. The company has no approved products and relies on financing, grants, and collaboration revenue.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Total Revenue | $78 | $1,398 |
| Net Income (Loss) | $(23,413) | $(1,824) |
| Operating Loss | $(55,654) | $(43,700) |
| Research & Development Expenses | $39,894 | $29,543 |
| General & Administrative Expenses | $15,838 | $15,555 |
| Cash Used in Operating Activities | $(43,217) | $(40,629) |
| Cash and Cash Equivalents (End of Period) | $147,606 | $160,324 |
| Total Debt (Long-term, net) | $52,851 | $0 |
| Contingent Value Rights (CVR) Liability | $356,700 | $392,100 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue dropped 94% to $78,000, primarily due to the cessation of grant revenue from the National Institute of Neurological Disorders and Stroke (NINDS) and no collaboration revenue recognized in the current period.
- Increased Operating Loss: Operating loss widened by 27% to $55.7 million, driven by a 35% increase in R&D expenses ($39.9M vs $29.5M). The increase in R&D was attributed to the Phase 3 AURORA trial for MG and Phase 2 TRITON trial for dermatomyositis.
- New Debt Financing: The company entered a Loan Agreement with K2 HealthVentures LLC in May 2026, borrowing $50.0 million. This introduced $852,000 in interest expense for the six-month period, compared to zero in the prior year.
- Non-Cash Gains/Losses:
- CVR Liability: Recognized a $35.4 million gain due to a decrease in the fair value of the CVR liability.
- Embedded Derivative: Recognized a $4.5 million loss on the change in fair value of an embedded derivative associated with the new debt.
- Equity Issuance: Raised approximately $19.3 million net through an "at the market" (ATM) offering program.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing cash, cash equivalents, and restricted cash ($149.3 million total) will fund operations for at least the next 12 months.
- Debt Covenants: The new Term Loan Facility includes restrictive covenants. Starting April 1, 2027, the company must maintain a minimum unrestricted cash balance of 80% of outstanding obligations if market cap is under $750 million. Starting January 1, 2029, a minimum trailing three-month net product revenue of $40.0 million is required.
- Future Funding: The company expects to continue incurring losses and will require additional capital to advance clinical trials and commercialization. Future funding may come from equity offerings, debt, or collaborations.
- Risk Factors: Key risks include the ability to access capital, clinical trial success, regulatory approvals, and compliance with debt covenants. The company has an accumulated deficit of $845.8 million.
Investor Verification Checklist
- Cash Runway: Verify the 12-month liquidity estimate against current burn rates and potential delays in clinical milestones.
- Debt Covenants: Monitor compliance with the new K2HV Loan Agreement, specifically the minimum cash balance covenant effective April 2027 and the revenue covenant effective 2029.
- CVR Liability Volatility: Assess the impact of the $356.7 million CVR liability on the balance sheet and the potential for future fair value adjustments affecting net income.
- Clinical Progress: Confirm the status and enrollment rates of the Phase 3 AURORA trial (MG) and Phase 2 TRITON trial (dermatomyositis), which are driving R&D costs.
- ATM Program Capacity: Note that approximately $78.9 million remains available under the current "at the market" sales agreement.